Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 639.65 Thousand USD | -50.08% |
| 2022 | 1.28 Million USD | -36.17% |
| 2021 | 2 Million USD | -23.01% |
| 2020 | 2.6 Million USD | -20.39% |
| 2019 | 3.27 Million USD | -22.81% |
| 2018 | 4.24 Million USD | -8.02% |
| 2017 | 4.61 Million USD | 1347.3% |
| 2016 | 318.67 Thousand USD | 319.15% |
| 2015 | 76.03 Thousand USD | 66.77% |
| 2014 | 45.58 Thousand USD | -38.05% |
| 2013 | 73.59 Thousand USD | -5.77% |
| 2012 | 78.1 Thousand USD | 6.62% |
| 2011 | 73.25 Thousand USD | -56.38% |
| 2010 | 167.95 Thousand USD | -30.02% |
| 2009 | 240 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 315.14 Thousand USD | -33.83% |
| 2024 Q1 | 476.29 Thousand USD | -25.54% |
| 2023 Q3 | 815.76 Thousand USD | -19.61% |
| 2023 Q2 | 1.01 Million USD | -15.35% |
| 2023 Q4 | 639.65 Thousand USD | -21.59% |
| 2023 FY | 639.65 Thousand USD | -50.08% |
| 2023 Q1 | 1.19 Million USD | -6.43% |
| 2022 Q1 | 1.81 Million USD | -9.57% |
| 2022 FY | 1.28 Million USD | -36.17% |
| 2022 Q4 | 1.28 Million USD | -11.71% |
| 2022 Q3 | 1.45 Million USD | -9.0% |
| 2022 Q2 | 1.59 Million USD | -12.13% |
| 2021 Q4 | 2 Million USD | -6.06% |
| 2021 FY | 2 Million USD | -23.01% |
| 2021 Q2 | 2.27 Million USD | -9.8% |
| 2021 Q1 | 2.52 Million USD | -3.27% |
| 2021 Q3 | 2.13 Million USD | -6.06% |
| 2020 Q4 | 2.6 Million USD | -4.58% |
| 2020 Q1 | 3.06 Million USD | -6.35% |
| 2020 FY | 2.6 Million USD | -20.39% |
| 2020 Q2 | 2.89 Million USD | -5.58% |
| 2020 Q3 | 2.73 Million USD | -5.65% |
| 2019 Q2 | 4.12 Million USD | 9.46% |
| 2019 Q1 | 3.76 Million USD | -11.22% |
| 2019 FY | 3.27 Million USD | -22.81% |
| 2019 Q3 | 3.41 Million USD | -17.2% |
| 2019 Q4 | 3.27 Million USD | -4.07% |
| 2018 FY | 4.24 Million USD | -8.02% |
| 2018 Q4 | 4.24 Million USD | -9.96% |
| 2018 Q3 | 4.71 Million USD | 9.98% |
| 2018 Q2 | 4.28 Million USD | -4.19% |
| 2018 Q1 | 4.47 Million USD | -3.06% |
| 2017 Q1 | 358.38 Thousand USD | 12.46% |
| 2017 Q2 | 203.38 Thousand USD | -43.25% |
| 2017 Q3 | 160.23 Thousand USD | -21.22% |
| 2017 Q4 | 4.61 Million USD | 2778.46% |
| 2017 FY | 4.61 Million USD | 1347.3% |
| 2016 Q3 | 264.45 Thousand USD | 158.19% |
| 2016 FY | 318.67 Thousand USD | 319.15% |
| 2016 Q4 | 318.67 Thousand USD | 20.5% |
| 2016 Q2 | 102.42 Thousand USD | -62.62% |
| 2016 Q1 | 274.01 Thousand USD | 260.4% |
| 2015 Q3 | 61.75 Thousand USD | 14.96% |
| 2015 Q1 | 64.6 Thousand USD | 41.72% |
| 2015 FY | 76.03 Thousand USD | 66.77% |
| 2015 Q4 | 76.03 Thousand USD | 23.12% |
| 2015 Q2 | 53.71 Thousand USD | -16.86% |
| 2014 Q3 | 99.01 Thousand USD | -49.49% |
| 2014 FY | 45.58 Thousand USD | -38.05% |
| 2014 Q4 | 45.58 Thousand USD | -53.96% |
| 2014 Q1 | 186 Thousand USD | 152.75% |
| 2014 Q2 | 196.04 Thousand USD | 5.39% |
| 2013 Q4 | 73.59 Thousand USD | 15.18% |
| 2013 FY | 73.59 Thousand USD | -5.77% |
| 2013 Q1 | 106.43 Thousand USD | 36.27% |
| 2013 Q2 | 73.92 Thousand USD | -30.55% |
| 2013 Q3 | 63.89 Thousand USD | -13.56% |
| 2012 Q4 | 78.1 Thousand USD | -91.94% |
| 2012 FY | 78.1 Thousand USD | 6.62% |
| 2012 Q1 | 1.02 Million USD | 3.75% |
| 2012 Q2 | 988.01 Thousand USD | -3.81% |
| 2012 Q3 | 968.53 Thousand USD | -1.97% |
| 2011 FY | 73.25 Thousand USD | -56.38% |
| 2011 Q3 | 100 Thousand USD | 0.0% |
| 2011 Q4 | 990 Thousand USD | 890.0% |
| 2010 FY | 167.95 Thousand USD | -30.02% |
| 2010 Q4 | 170 Thousand USD | 0.0% |
| 2009 FY | 240 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -27590.736% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 67.334% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 93.939% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -15.855% |
| Rebus Holdings, Inc. | 5000.00 USD | -12693.12% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.509% |
| Qrons Inc. | 420.00 USD | -152199.048% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 16.997% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 97.711% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -33.107% |
| Skye Bioscience, Inc. | 11.94 Million USD | 94.643% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.353% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 91.14% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -737.75% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.403% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 55.332% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -783.93% |
| Mesoblast Limited | 667.9 Million USD | 99.904% |
| Marizyme, Inc. | 22.01 Million USD | 97.094% |
| Genus plc | 1.02 Billion USD | 99.938% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 52.909% |
| Pharming Group N.V. | 462.85 Million USD | 99.862% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 80.693% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -28.178% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2.019% |
| ContraFect Corporation | 20.67 Million USD | 96.907% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -63.861% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -67.372% |
| IMV Inc. | 31.33 Million USD | 97.959% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 84.572% |
| MultiCell Technologies, Inc. | 126.22 USD | -506678.64% |
| ONE Bio Corp. | 70.08 Million USD | 99.087% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 31.929% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.502% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -48.167% |
| Q BioMed Inc. | 3.51 Million USD | 81.805% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.182% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -144.819% |
| Biomind Labs Inc. | 73.81 Thousand USD | -766.519% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.857% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 55.851% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 97.869% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 76.709% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 6.957% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 75.428% |
| GB Sciences, Inc. | 103.44 Thousand USD | -518.372% |
| Alpha Cognition Inc. | 2.45 Million USD | 73.915% |
| HST Global, Inc. | 1526.00 USD | -41817.169% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 35.255% |
| Halberd Corporation | 10.13 Thousand USD | -6213.849% |
| Enzolytics Inc. | 361.7 Million USD | 99.823% |
| Agentix Corp. | 261.39 Thousand USD | -144.711% |
| Resverlogix Corp. | 8.11 Million USD | 92.118% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 65.937% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.986% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.659% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2707.849% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 92.852% |
| AVAX Technologies, Inc. | 7.37 Million USD | 91.329% |
| Zenith Capital Corp. | 7410.00 USD | -8532.335% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.981% |
| Ember Therapeutics, Inc. | 184.00 USD | -347539.13% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -98.771% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -144.738% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 31.069% |
| Kadimastem Ltd | 2.3 Million USD | 72.238% |
| Helix BioMedix, Inc. | 3.02 Million USD | 78.855% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.786% |
| BioStem Technologies, Inc. | 14.56 Million USD | 95.607% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1020.356% |
| LadRx Corporation | 2.3 Million USD | 72.284% |
| Cell Source, Inc. | 195.17 Thousand USD | -227.741% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -80.889% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -80.889% |
| NovAccess Global Inc. | 62.24 Thousand USD | -927.593% |
| Affymax, Inc. | 7.44 Million USD | 91.406% |
| Itoco Inc. | 1.4 Million USD | 54.313% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -568.698% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -503.449% |
| Mobile Lads Corp. | 52.00 USD | -1230007.692% |
| CytoDyn Inc. | 11.13 Million USD | 94.256% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -347.399% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -3477.494% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -65.941% |
| SYBLEU INC | 330.46 Thousand USD | -93.561% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -56.234% |
| International Stem Cell Corporation | 5.39 Million USD | 88.133% |
| Bioxytran, Inc. | 137.63 Thousand USD | -364.738% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 95.736% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 96.142% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -709.691% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 26.024% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 91.491% |
| Neutra Corp. | 2851.00 USD | -22336.198% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.026% |
| PureTech Health plc | 693.97 Million USD | 99.908% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 92.075% |
| IXICO plc | 15.84 Million USD | 95.963% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 92.277% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.381% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Cellectis S.A. | 333.99 Million USD | 99.808% |